TOP TEN perturbations for 1184_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1184_at
Selected probe(set): 201762_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1184_at (201762_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):2.9884262
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.9758625
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

inclusion body myositis study 2 / normal quadriceps tissue

Relative Expression (log2-ratio):2.7948427
Number of Samples:5 / 2
Experimental inclusion body myositis study 2
Quadriceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal quadriceps tissue
Quadriceps femoris biopsy muscle samples from control subjects.

expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)

Relative Expression (log2-ratio):2.682929
Number of Samples:2 / 3
Experimental expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS).
Control expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.4935074
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

TNF-ɑ; TGF-ß2 study 1 (intermediate) / untreated ARPE-19 cell sample

Relative Expression (log2-ratio):2.4785051
Number of Samples:6 / 3
Experimental TNF-ɑ; TGF-ß2 study 1 (intermediate)
ARPE-19 retina pigment epithelial cell samples treated with TNF-ɑ (10 ng/ml) and TGF-ß2 (5 ng/ml). Samples were taken 16 and 24 hours after treatment.
Control untreated ARPE-19 cell sample
Untreated ARPE-19 retina pigment epithelial cell samples harvested before adding TNF-ɑ (10 ng/ml) and TGF-ß2 (5 ng/ml).

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.349594
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

memory T-cell activation study 1 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):2.289589
Number of Samples:3 / 3
Experimental memory T-cell activation study 1
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

TNF-ɑ; TGF-ß2 study 1 (late) / untreated ARPE-19 cell sample

Relative Expression (log2-ratio):2.2573252
Number of Samples:6 / 3
Experimental TNF-ɑ; TGF-ß2 study 1 (late)
ARPE-19 retina pigment epithelial cell samples treated with TNF-ɑ (10 ng/ml) and TGF-ß2 (5 ng/ml). Samples were taken 42 and 60 hours after treatment.
Control untreated ARPE-19 cell sample
Untreated ARPE-19 retina pigment epithelial cell samples harvested before adding TNF-ɑ (10 ng/ml) and TGF-ß2 (5 ng/ml).

hCMV study 1 (CD69+) / uninfected CD4 T-LGL sample (diseased)

Relative Expression (log2-ratio):2.1670542
Number of Samples:4 / 3
Experimental hCMV study 1 (CD69+)
CD69+ human cytomegalovirus (hCMV)-stimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.
Control uninfected CD4 T-LGL sample (diseased)
Unstimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis.